Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221489 | 0.78 | KMT2A (0.52) | MMP12NPC1LMNAF10F2 | |
| SCHEMBL7056381 | 0.74 | TSHR (0.53) | MMP12ALDH1A1NPC1CNR2 | |
| SCHEMBL7061349 | 0.73 | SMN1; SMN2 (0.49) | ALDH1A1CNR2PRSS1 | |
| SCHEMBL13752641 | 0.72 | DPP4 (0.40) | MMP12NPC1LMNAF10F2 | |
| SCHEMBL7058224 | 0.71 | TSHR (0.51) | ALDH1A1NPC1 | |
| SCHEMBL3622726 | 0.71 | ALDH1A1 (0.43) | ALDH1A1LMNALTA4H | |
| SCHEMBL7055434 | 0.71 | PRSS1 (0.48) | ALDH1A1LMNAPRSS1 | |
| SCHEMBL27534106 | 0.70 | TSHR (0.46) | ALDH1A1LTA4HCNR2 | |
| Hydrochloric Acid SCHEMBL540416 | 0.70 | ALDH1A1 (0.45) | ALDH1A1LTA4H | |
| Hydrochloric Acid SCHEMBL27850080 | 0.70 | ALDH1A1 (0.45) | ALDH1A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | MMP12 1318/4885ALDH1A1 199/4885HIF1A 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.